123 related articles for article (PubMed ID: 8726834)
1. Role of endogenous platelet-activating factor in the regulation of pancreatic blood flow during caerulein stimulation.
Ogura M; Kubota Y; Inoue K
J Gastroenterol; 1996 Jun; 31(3):414-9. PubMed ID: 8726834
[TBL] [Abstract][Full Text] [Related]
2. Role of endogenous platelet-activating factor in caerulein-induced acute pancreatitis in rats: protective effects of a PAF-antagonist.
Fujimura K; Kubota Y; Ogura M; Yamaguchi T; Binnaka T; Tani K; Kitagawa S; Mizuno T; Inoue K
J Gastroenterol Hepatol; 1992; 7(2):199-202. PubMed ID: 1571504
[TBL] [Abstract][Full Text] [Related]
3. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis. A morphologic and functional study in the rat.
Tomaszewska R; Dembiński A; Warzecha Z; Banaś M; Konturek SJ; Stachura J
J Physiol Pharmacol; 1992 Dec; 43(4):345-52. PubMed ID: 1294265
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor mediates pancreatic function derangement in caerulein-induced pancreatitis in rats.
Alonso R; Montero A; Arévalo M; García LJ; Sánchez-Vicente C; Rodríguez-Nodal F; López-Novoa JM; Calvo JJ
Clin Sci (Lond); 1994 Jul; 87(1):85-90. PubMed ID: 7520381
[TBL] [Abstract][Full Text] [Related]
5. Effect of proglumide, a cholecystokinin receptor antagonist, on caerulein-stimulated pancreatic enzyme secretion and pancreatic polypeptide release in the dog.
Fried M; Beglinger C; Koehler E; Whitehouse I; Varga L; Gyr K
Regul Pept; 1984 Mar; 8(2):117-22. PubMed ID: 6729149
[TBL] [Abstract][Full Text] [Related]
6. Effect of the cholecystokinin-receptor antagonist lorglumide on pancreatic enzyme secretion stimulated by bombesin, food, and caerulein, giving similar plasma cholecystokinin concentrations in the dog.
de Jong AJ; Singer MV; Jansen JB; Niebel W; Rovati LC; Lamers CB
Gut; 1991 Feb; 32(2):215-9. PubMed ID: 1864545
[TBL] [Abstract][Full Text] [Related]
7. Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat.
Scarpignato C; Varga G; Dobronyi I; Papp M
Br J Pharmacol; 1989 Mar; 96(3):661-9. PubMed ID: 2470456
[TBL] [Abstract][Full Text] [Related]
8. Role of nitric oxide in the pancreatic blood flow response to caerulein.
Satoh A; Shimosegawa T; Abe T; Kikuchi Y; Abe R; Koizumi M; Toyota T
Pancreas; 1994 Sep; 9(5):574-9. PubMed ID: 7528917
[TBL] [Abstract][Full Text] [Related]
9. Effects of prostaglandin of E, F and I series, leukotriene C and platelet activating factor on amylase release from isolated rat pancreatic acini.
Jaworek J; Konturek SJ
J Physiol Pharmacol; 1993 Dec; 44(4):365-81. PubMed ID: 7510150
[TBL] [Abstract][Full Text] [Related]
10. Effects of CCK receptor blockade on intestinal motor activity in conscious dogs.
Niederau C; Karaus M
Am J Physiol; 1991 Feb; 260(2 Pt 1):G315-24. PubMed ID: 1996649
[TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas.
Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z
J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.
Niederau M; Niederau C; Strohmeyer G; Grendell JH
Am J Physiol; 1989 Jan; 256(1 Pt 1):G150-7. PubMed ID: 2463767
[TBL] [Abstract][Full Text] [Related]
13. Role of cholecystokinin in the intestinal phase of pancreatic circulation in dogs.
Nakajima M; Naruse S; Kitagawa M; Ishiguro H; Jin C; Ito O; Hayakawa T
Am J Physiol Gastrointest Liver Physiol; 2001 Apr; 280(4):G614-20. PubMed ID: 11254487
[TBL] [Abstract][Full Text] [Related]
14. Effect of a cholecystokinin receptor antagonist (loxiglumide) on gallbladder contractile function in guinea pigs.
Tsubo K; Arai M; Omachi H; Mitamura K
J Gastroenterol; 1996 Aug; 31(4):578-81. PubMed ID: 8844481
[TBL] [Abstract][Full Text] [Related]
15. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K
Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340
[TBL] [Abstract][Full Text] [Related]
16. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
Otsuki M; Nakano S; Tachibana I
Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
[TBL] [Abstract][Full Text] [Related]
17. Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.
Watanabe N; Otsuki M
Int J Pancreatol; 1993 Apr; 13(2):129-37. PubMed ID: 8501354
[TBL] [Abstract][Full Text] [Related]
18. Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat.
Sperti C; Militello C; Rovati L; Behboo R; Khajeturian E; Perasole A; Alaggio R; Pedrazzoli S
J Surg Oncol; 1994 Sep; 57(1):11-6. PubMed ID: 8065144
[TBL] [Abstract][Full Text] [Related]
19. The action of scretin, cholecystokinin-pancreozymin and caerulein on pancreatic secretion in the rat.
Dockray GJ
J Physiol; 1972 Sep; 225(3):679-92. PubMed ID: 5076393
[TBL] [Abstract][Full Text] [Related]
20. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats.
Konturek SJ; Dembinski A; Konturek PJ; Warzecha Z; Jaworek J; Gustaw P; Tomaszewska R; Stachura J
Gut; 1992 Sep; 33(9):1268-74. PubMed ID: 1385272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
